medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2007, Number 05

<< Back Next >>

Ginecol Obstet Mex 2007; 75 (05)

Cardiovascular disease as a current threat of older women. Relation to estrogens

Zárate A, Saucedo R, Basurto L, Martínez C

Language: Spanish
References: 44
Page: 286-292
PDF size: 319.15 Kb.


ABSTRACT

Cardiovascular disease (CVD) is the leading cause of death in women around the world. Cardiovascular disease risk increases after the menopause which may be related to metabolic and hormonal changes. The decline in ovarian function with menopause is associated with spontaneous increases in proinflammatory cytokines. Chronic inflammation is a major factor that drives the progression of atherosclerosis and atherothrombosis. Measurement of the inflammatory markers has been postulated as a method of determining increased risk of cardiovascular disease in apparently healthy older women. Endogenous estrogen appears to be cardioprotective and several observational epidemiological studies have suggested that hormone therapy reduces the risk of coronary events in healthy postmenopausal women. However, recent clinical studies failed to show such beneficial effect. Among the mechanism that may account for the effects of hormone therapy on cardiovascular disease is inflammation.


REFERENCES

  1. Alexander J, Clearfield M. Cardiovascular disease after menopause: a growing epidemic. Minerva Ginecol 2006;58:35-40.

  2. Witteman JC, Grobbee DE, Kok FJ, Hofman A, Valkenburg HA. Increased risk of atherosclerosis in women after the menopause. Br Med J 1989;298:642-4.

  3. Sites CK, Toth MJ, Cushman M, L’Hommedieu GD, Tchernof A, Tracy RP. Menopause-related differences in inflammation markers and their relationship to body fat distribution and insulin-stimulated glucose disposal. Fertil Steril 2002;77:128-35.

  4. Toth MJ, Tchernof A, Sites CK, Poehlman ET. Effect of menopausal status on body composition and abdominal fat distribution. Int J Obesity 2000;24:226-31.

  5. Hak AE, Stehouwer DA, Bots ML, Polderman KH, Schalkwijk CG, Westendorp IC. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol 1999;19:1986-91.

  6. Lindoff C, Petersson F, Lecander I, Martinsson G, Astedt B. Passage of the menopause is followed by haemostatic changes. Maturitas 1993;17:17-22.

  7. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 2003;88:2404-11.

  8. Writing Group for the Women’s Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321-33.

  9. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age of hormone initiation. J Womens Health 2006;15:35-44.

  10. Allison MA, Manson JE. Observational studies and clinical trials of menopausal hormone therapy: can they both be right? Menopause 2006;13:1-3.

  11. Harman SM, Brinton EA, Cedars M. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 2005;8:3-12.

  12. Manson JE, Bassuk SS, Harman SM, Brinton EA, Cedars MI, Lobo R. Postmenopausal hormone therapy: new questions and the case for new clinical trials. Menopause 2006;13:139-47.

  13. Klaiber E, Vogel W, Rako S. A critique of the Women’s Health Initiative hormone therapy study. Fertil Steril 2005;84:1589-601.

  14. Gruber CJ, Tschugguel W, Schneeberger C, Huber JC. Production and action of estrogens. N Engl J Med 2002;346:340-52.

  15. Weiner CP, Lizasoain I, Baylis SA. Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci USA 1994;91:5212-6.

  16. Hu FB, Grodstein F. Postmenopausal hormone therapy and the risk of cardiovascular disease: The epidemiological evidence. Am J Cardiol 2002;90:26F.

  17. Miller AP, Chen Y, Xing D, Feng W, Oparil S. Hormone replacement therapy and inflammation. Interactions in cardiovascular disease. Hypertension 2003;42:657-63.

  18. Meade TW, Dyer S, Howarth DJ. Antithrombin III and procoagulant activity: sex differences and effect of the menopause. Br J Haematol 1990;74:77-81.

  19. Davison S, Davis SR. New markers for cardiovascular disease risk in women: impact of endogenous oestrogen status and exogenous postmenopausal hormone therapy. J Clin Endocrinol Metab 2003;88:2470-8.

  20. Pfeilschifter J, Koditz R, Pfohl M, Schatz H. Changes in proinflammatory cytokine activity after menopause. Endocr Rev 2002;23:90-119.

  21. Baldwin A. The transcription factor NF-kB and human disease. J Clin Invest 2001;107:3-6.

  22. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-26.

  23. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-74.

  24. Rubanyi GM. The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol 1993;22:1-14.

  25. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95.

  26. Frostegard J, Ulfgren AK, Nyberg P. Cytokine expression in advanced human atherosclerotic plaques: dominance of proinflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 1999;145:33-43.

  27. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990;265:621-36.

  28. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993;82:513-20.

  29. Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med 2002;252:283-94.

  30. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102:2165-8.

  31. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M. Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.

  32. Tonetti MS, D’Aiuto F, Nibali L, Storry AD, Parkar M, Suvan J. Treatment of periodontitis and endothelial function. N Engl J Med 2007;356:911-20.

  33. Zárate A, Saucedo R, Basurto L. El tejido adiposo: una nueva glándula del sistema endocrino. Ciencia 2007;58:69-76.

  34. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005;96:939-49.

  35. Rachón D, Suchecka RK, Hak L, My’sliwska J. Effects of intranasal 17β-estradiol administration on serum bioactive interleukin-6 and C-reactive protein levels in healthy postmenopausal women. Menopause 2006;13:840-5.

  36. Basurto L, Saucedo R, Zárate A, Martínez C, et al. Effect of pulsed estrogen therapy on hemostatic markers in comparison with oral estrogen regimen in postmenopausal women. Gynecol Obstet Invest 2006;61:61-4.

  37. Taner MZ, Ozpolat E, Taskiran C, Onan MA, et al. Effects of four different regimens of hormone replacement therapy on hemostatic parameters: a prospective randomized study. Maturitas 2006;53:267-73.

  38. Saucedo R, Rico G, Basurto L, Ochoa R, Zárate A. Transdermal estradiol in menopausal women depresses interleukin-6 without affecting other markers of immune response. Gynecol Obstet Invest 2002;53:114-7.

  39. Martínez C, Basurto L, Zárate A, Saucedo R, Gaminio E, Collazo J. Transdermal estradiol does not impair hemostatic biomarkers in postmenopausal women. Maturitas 2005;50:39-43.

  40. Salpeter SR, Walsh JM, Ormiston TM, Greyber E, Buckley NS. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 2006;8:538-54.

  41. Zegura B, Keber I, Sebastjen M, Koening W. Double blind, randomized study of estradiol replacement therapy on markers of inflammation, coagulation and fibrinolysis. Atherosclerosis 2003;168:123-9.

  42. Cooper BC, Burger NZ, Cushman M, Sites CK. Insulin resistance with hormone replacement therapy: association with markers of inflammation and adiposity. Am J Obstet Gynecol 2007;196:123-7.

  43. Saucedo R, Basurto L, Zárate A, Martínez C, Hernández M, Galván R. Association of plasminogen activator inhibitor type 1 (PAI-1) with insulin resistance in menopausal women. The effect of estradiol therapy. Gynecol Obstet Invest 2007;64:61-64.

  44. Canonico M, Oger E, Plu-Bureau G, Meyer G, et al. Estrogen and thromboembolism risk (ESTHER) Study Group. Circulation 2007;115:820-2.




2020     |     www.medigraphic.com